{"id":"W2096928121","doi":"10.1186/1742-6405-7-30","title":"Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)","year":2010,"lang":"en","type":"article","venue":"AIDS Research and Therapy","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; ACT Government; York University; Tulane University; Bristol-Myers Squibb; University of Washington; University of Rochester; University of Southern California; Ohio State University","keywords":"Medicine; Antiretroviral therapy; Internal medicine; Clinical trial; Randomized controlled trial; Toxicity; Interleukin; Human immunodeficiency virus (HIV); Viral load; Immunology; Gastroenterology; Cytokine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001100046,0.0002959561,0.000523364,0.0004849708,0.0002097139,0.00007738482,0.000326778,0.0002849521,0.001026281],"category_scores_gemma":[0.0001535912,0.0001674249,0.00007957834,0.000595376,0.0006540845,0.0002444344,0.00008177051,0.0009892149,0.00005635837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004002937,"about_ca_system_score_gemma":0.0002447354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005291008,"about_ca_topic_score_gemma":0.000144003,"domain_scores_codex":[0.9970663,0.0007176675,0.000426459,0.0005113668,0.0003048779,0.0009733461],"domain_scores_gemma":[0.9986116,0.0003656231,0.0001324277,0.0004408436,0.000341894,0.0001076045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4317024,0.003153884,0.2034316,0.00003099755,0.00030649,0.00002355887,0.0004090971,4.527364e-8,0.1099104,0.00004979073,0.0002268883,0.2507549],"study_design_scores_gemma":[0.4388841,0.1461769,0.06740608,0.0002041445,0.000005628322,0.00001126525,0.0001569609,0.00000241474,0.253388,0.00008832035,0.09324428,0.000432012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7113895,0.0000148065,4.99668e-7,0.00001838526,0.0000207316,0.2878488,0.00005934812,0.00002318187,0.0006247083],"genre_scores_gemma":[0.6276613,0.00003241843,0.00004528769,0.000007786034,0.000029119,0.3709677,0.00004451094,0.00002628118,0.001185518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2503229,"threshold_uncertainty_score":0.9998869,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03795704294206537,"score_gpt":0.3681745876916406,"score_spread":0.3302175447495752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}